SEARCH

SEARCH BY CITATION

References

  • 1
    Anderson KE. The porphyrias (Chapter 72). In: BoyerT, WrightT, MannsM, eds. Zakim and Boyer's Hepatology: A Textbook of Liver Diseases. Philadelphia, PA: Elsevier; 2006. : 13911432.
  • 2
    Elder GH. Porphyria cutanea tarda and related disorders. In: KadishKM, SmithK, GuilardR, eds. Porphyrin Handbook, Part II. Vol. 14. San Diego, CA: Academic Press, 2003: 6792.
  • 3
    Egger NG, Goeger DE, Payne DA, Miskovsky EP, Weinman SA, Anderson KE. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 2002; 47: 419426.
  • 4
    Ratnaike S, Blake D, Campbell D, Cowen P, Varigos G. Plasma ferritin levels as a guide to the treatment of porphyria cutanea tarda by venesection. Australas J Dermatol 1988; 29: 37.
  • 5
    Schmid R. Cutaneous porphyria in Turkey. N Engl J Med 1960; 263: 397398.
  • 6
    Phillips JD, Jackson LK, Bunting M, Franklin MR, Thomas KR, Levy JE, et al. A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci U S A 2001; 98: 259264.
  • 7
    Sinclair PR, Gorman N, Dalton T, Walton HS, Bement WJ, Sinclair JF, et al. Uroporphyria produced in mice by iron and 5-aminolaevulinic acid does not occur in Cyp1a2(−/−) null mutant mice. Biochem J 1998; 330: 149153.
  • 8
    Sinclair PR, Gorman N, Walton HS, Bement WJ, Szakacs J, Gonzalez FJ, et al. Relative roles of CYP2E1 and CYP1A2 in mouse uroporphyria caused by acetone. Arch Biochem Biophys 2000; 384: 383390.
  • 9
    Sinclair PR, Gorman N, Walton HS, Bement WJ, Dalton TP, Sinclair JF, et al. CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene and iron. Toxicol Appl Pharmacol 2000; 162: 6067.
  • 10
    Smith AG, Clothier B, Carthew P, Childs NL, Sinclair PR, Nebert DW, et al. Protection of the Cyp1A2(−/−) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol 2001; 173: 8998.
  • 11
    Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in nonhemochromatotic liver disease. Alcohol 2003; 30: 137144.
  • 12
    Smith A. Porphyria caused by chlorinated AH receptor ligands and associated mechanisms of liver injury and cancer. In: KadishKM, SmithK, GuilardR, eds. Porphyrin Handbook, Part II. Vol. 14. San Diego, CA: Academic Press, 2003: 169210.
  • 13
    Elder GH, Urquhart AJ, de Salamanca RE, Munoz JJ, Bonkovsky HL. Immunoreactive uroporphyrinogen decarboxylase in the liver in porphyria cutanea tarda. Lancet 1985; 2: 229233.
  • 14
    Percy VA, Naidoo D, Joubert SM, Pegoraro RJ. Ascorbate status of patients with porphyria cutanea tarda symptomatica and its effect on porphyrin metabolism. S Afr J Med Sci 1975; 40: 185196.
  • 15
    Sinclair PR, Gorman G, Shedlofsky SI, Honsinger C, Sinclair JF, Karagas MR, et al. Ascorbic acid deficiency in porphyria cutanea tarda. J Lab Clin Med 1997; 130: 197201.
  • 16
    Rocchi E, Casalgrandi G, Masini A, Giovannini F, Ceccarelli D, Ferrali M, et al. Circulating pro- and antioxidant factors in iron and porphyrin metabolism disorders. Ital J Gastroenterol Hepatol 1999; 31: 861867.
  • 17
    Gorman N, Zaharia A, Trask HS, Szakacs JG, Jacobs NJ, Jacobs JM, et al. Effect of iron and ascorbate on uroporphyria in ascorbate-requiring mice as a model for porphyria cutanea tarda. HEPATOLOGY 2007; 45: 187194.
  • 18
    Sinclair PR, Gorman N, Walton HS, Bement WJ, Jacobs JM, Sinclair JF. Ascorbic acid inhibition of cytochrome P450-catalyzed uroporphyrin accumulation. Arch Biochem Biophys 1993; 304: 464470.
  • 19
    Sinclair PR, Gorman N, Sinclair JF, Walton HS, Bement WJ, Lambrecht RW. Ascorbic acid inhibits chemically induced uroporphyria in ascorbate-requiring rats. HEPATOLOGY 1995; 22: 565572.
  • 20
    Taljaard JJF, Shanley BC, Stewart-Wynne EG, Deppe WM, Joubert SM. Studies on low dose chloroquine therapy and the action of chloroquine in symptomatic porphyria. Br J Dermatol 1972; 87: 261269.
  • 21
    Ashton RE, Hawk JLM, Magnus IA. Low-dose oral chloroquine in the treatment of porphyria cutanea tarda. Br J Dermatol 1984; 3: 609613.
  • 22
    Bulaj ZJ, Franklin MR, Phillips JD, Miller KL, Bergonia HA, Ajioka RS, et al. Transdermal estrogen replacement therapy in postmenopausal women previously treated for porphyria cutanea tarda. J Lab Clin Med 2000; 136: 482488.
  • 23
    Fargion S, Piperno A, Cappellini MD, Sampietro M, Fracanzani AL, Romano R, et al. Hepatitis-C virus and porphyria cutanea tarda—evidence of a strong association. HEPATOLOGY 1992; 16: 13221326.
  • 24
    Berk PD. An editor's look-back. HEPATOLOGY 2006; 43( Suppl 1): S13S30.
  • 25
    Christiansen L, Bygum A, Jensen A, Thomsen K, Brandrup F, Horder M, et al. Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum Genet 2000; 107: 612614.